Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: User-generated input is received via a graphical user interface specifying a plurality of interconnected business actions. Based on such input, a business logic tree is generated which has a plurality of hierarchical nodes each having a unique identifier. Thereafter, the business logic tree is converted into programming language code including embedded references to the unique identifiers. The programming language code is later executed and results of such execution are logged in relation to the embedded references. Related apparatus, systems, techniques and articles are also described.

Abstract: Data is received by an omniscient debugger that comprises a plurality of execution traces of a sample data set and a corresponding logic tree. The logic tree includes a hierarchical representation of a plurality of instructions for an application and the execution traces comprise results of the logic tree being applied to the sample data set. Thereafter, a repository is polled to obtain a baseline corresponding to the sample data set. Differences are then identified between each of the execution traces and the baseline. Later, debugging requests are received and information relating to same can be provided based on the identified differences. Related apparatus, systems, techniques and articles are also described.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A system is presented by which a consumer such as an insurance applicant may procure a testing process in a comparative manner to facilitate comprehension of their health state relative to others in their community. Physical heath measurements and blood and urine samples are taken from an applicant through, for example, a visit by a phlebotomist or other medical practitioner. Physical readings are then sent to a third party laboratory that produces a risk assessment score for the applicant and notes other data potentially affecting lifespan longevity of the applicant. That information is then transmitted to a life expectancy processor to calculate various life expectancy values and establish a comparative life expectancy ranking for the applicant. A life expectancy ranking is then produced relative to others in the applicant's community, and that ranking is displayed in a graphical format to facilitate understanding by the applicant as to their relative health.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Disclosed herein is a panel system for covering a building wall. The panel system includes at least one panel assembly. Each panel assembly includes a panel having a front panel wall, a side panel wall, and a back mounting flange overhanging the front panel wall. Each panel also includes at least one perimeter extrusion. Each perimeter extrusion includes a panel engaging portion having a panel slot shaped to receive the back mounting flange of the panel, and a connector engaging portion having a connector slot. The panel system also includes at least one connector extrusion for mounting the panel assembly to the building wall. Each connector extrusion includes a connector base mountable to the building wall, and at least one connector flange shaped to fit in the connector slot of the perimeter extrusion.

Abstract: A panel flange bending tool is disclosed, which includes a head coupled to an arm. The head includes a panel engaging portion, first and second bending corners, and an abutment. The panel engaging portion includes a flange slot having a slot plane extending in a proximal direction from a distal slot opening to a proximal slot end, the slot opening sized to receive a panel flange. The first bending corner is aligned with the flange slot, and the first and second bending corners define a first bending plane. The abutment extends proximal of the first and second bending corners. The second bending corner and the abutment define a second bending plane. The slot plane, the first bending plane, and the second bending plane intersect each other triangularly at first and second internal bending angles. The first and second internal bending angles are less than or equal to 90 degrees.

Abstract: A panel flange bending tool is disclosed, which includes a head coupled to an arm. The head includes a panel engaging portion, first and second bending corners, and an abutment. The panel engaging portion includes a flange slot having a slot plane extending in a proximal direction from a distal slot opening to a proximal slot end, the slot opening sized to receive a panel flange. The first bending corner is aligned with the flange slot, and the first and second bending corners define a first bending plane. The abutment extends proximal of the first and second bending corners. The second bending corner and the abutment define a second bending plane. The slot plane, the first bending plane, and the second bending plane intersect each other triangularly at first and second internal bending angles. The first and second internal bending angles are less than or equal to 90 degrees.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: An implantable lead includes an expandable paddle body and a plurality of electrodes disposed on the paddle body. The electrodes are configured and arranged to provide electrical stimulation to adjacent tissue when implanted and the lead is coupled to a control module. The paddle body is configured for percutaneous implantation through an introducer followed by expansion of a volume of the paddle body by at least 10%. Alternatively, the paddle body is configured for percutaneous implantation and when implanted the lead is configured and arranged so that a position or orientation of the plurality of electrodes relative to the paddle body can be altered.

Abstract: A perimeter extrusion for mounting a panel to a building wall is disclosed. The perimeter extrusion includes a panel engaging portion, and an anchor engaging portion. The panel engaging portion has a fastener slot sized to receive a fastener, which includes a slot upper wall opposite and spaced apart from a slot lower wall by a slot inner wall connecting the slot upper and lower walls at the slot inner end, and a slot outer end defining a slot opening. Each slot upper and lower wall has an interior face extending between the slot inner and outer ends, and at least a portion of at least one of the interior faces is serrated for engaging a fastener. The anchor engaging portion is connected to the panel engaging portion and has an anchor slot sized to receive an anchor flange of an anchor extrusion.